Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NRx Pharmaceuticals, Inc. (NRXP)
USD4.36
+0.21 (+5.06%)
US NASDAQ Healthcare Biotechnology
Address
1201 Orange Street 19801
Wilmington, DE, US
Wilmington, DE, US
CEO
Jonathan C. Javitt
Website
nrxpharma.com
IPO
2017-12-04
CIK 1719406 ISIN US6294442099
Also trades on
NASDAQ Global Market · NRXP (USD)
NASDAQ Global Market · NRXPW (USD)
Description
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| BRPA and Merger Sub. | BRPAU | 2021-01-27 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.36
+0.21 (+5.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.19
Float Shares
14.48M
Free Float %
83.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.18% | +6.84% | +28.63% | +82.22% | +55.45% | +21.03% | +34.43% | -51.76% | -98.42% | -96.58% | -96.58% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
4.36
Low
2.00
-54.1%
Consensus
2.00
-54.1%
Median
2.00
-54.1%
High
2.00
-54.1%
DCF (Unlevered)
0.75
-82.9%
DCF (Levered)
0.59
-86.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
2.00
-54.1%
|
Quality scores
Altman Z-Score
-45.64
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+43.9% ★ Q1'26: +87.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,249.6% Q1'26: -402.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,321.5% Q1'26: -444.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +96.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+103.5% Q1'26: +97.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 6.70M (-100.0%)
|
1.23M
est: 11.81M (-89.6%)
|
85.87M
28.21M – 143.53M
+627.1% YoY
|
301.74M
116.70M – 486.77M
+251.4% YoY
|
732.00M
148.84M – 1.34B
+142.6% YoY
|
1.28B
260.59M – 2.35B
+75.1% YoY
|
1.42B
288.33M – 2.60B
+10.6% YoY
|
| EBITDA |
-24.04M
est: 4.02M (-698.1%)
|
-16.04M
est: 7.09M (-326.4%)
|
51.52M
16.93M – 86.12M
+627.1% YoY
|
181.04M
70.02M – 292.06M
+251.4% YoY
|
439.20M
89.30M – 806.25M
+142.6% YoY
|
768.96M
156.35M – 1.41B
+75.1% YoY
|
850.83M
173.00M – 1.56B
+10.6% YoY
|
| EBIT |
-24.05M
est: 4.02M (-698.2%)
|
-16.19M
est: 7.09M (-328.4%)
|
51.52M
16.93M – 86.12M
+627.1% YoY
|
181.04M
70.02M – 292.06M
+251.4% YoY
|
439.20M
89.30M – 806.25M
+142.6% YoY
|
768.96M
156.35M – 1.41B
+75.1% YoY
|
850.83M
173.00M – 1.56B
+10.6% YoY
|
| Net Income |
-25.13M
est: -24.11M (-4.2%)
|
-28.62M
est: -22.19M (-29.0%)
|
10.83M
-12.25M – 33.91M
+148.8% YoY
|
41.90M
24.22M – 59.58M
+286.8% YoY
|
180.20M
68.06M – 292.35M
+330.0% YoY
|
329.91M
-11.77M – 688.33M
+83.1% YoY
|
323.38M
-11.54M – 674.71M
-2.0% YoY
|
| SGA |
13.50M
est: 19.65M (-31.3%)
|
13.06M
est: 34.63M (-62.3%)
|
251.81M
82.72M – 420.90M
+627.1% YoY
|
884.81M
342.21M – 1.43B
+251.4% YoY
|
2.15B
436.45M – 3.94B
+142.6% YoY
|
3.76B
764.14M – 6.90B
+75.1% YoY
|
4.16B
845.49M – 7.63B
+10.6% YoY
|
| EPS |
-2.39
est: -1.91 (-25.3%)
|
-1.34
est: -1.04 (-29.2%)
|
0.53
-0.57 – 1.58
+150.9% YoY
|
1.97
1.13 – 2.78
+272.8% YoY
|
8.42
3.18 – 13.66
+327.6% YoY
|
15.42
-0.55 – 32.16
+83.1% YoY
|
15.11
-0.54 – 31.53
-2.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | D. Boral Capital | Buy | Buy | Maintain |
| 2026-04-27 | Ascendiant Capital | Buy | Buy | Maintain |
| 2026-04-23 | D. Boral Capital | Buy | Buy | Maintain |
| 2026-04-20 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.87M
OE per share TTM
-0.12
Owner's Yield
-3.65%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
51.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
37
Total invested
13.15M
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Daniel Javitt | 28.79M | 60.66% | — | 28.79M | 13.97M | — | IN | United States | 2021-06-03 | ↗ |
| 2 | Jonathan C. Javitt | 14.87M | 22.30% | — | — | 14.87M | — | IN | — | 2022-06-03 | ↗ |
| 3 | C. Javitt | 9.87M | 14.60% | — | 9.87M | 9.87M | — | IN | USA | 2022-09-13 | ↗ |
| 4 | M. Nussbaum | 1.64M | 18.10% | — | 1.64M | — | 1.64M | IN | States | 2018-11-26 | ↗ |
| 5 | Lending Group LLC | 1.50M | 16.60% | 1.50M | — | 1.50M | — | OO | Delaware | 2018-11-26 | ↗ |
| 6 | Levine | 1.16M | 2.44% | 66.6K | 1.10M | 66.6K | 1.10M | IN | States | 2021-06-04 | ↗ |
| 7 | Nussbaum | 1.16M | 2.44% | 66.6K | 1.10M | 66.6K | 1.10M | IN | States | 2021-06-04 | ↗ |
| 8 | Big Rock Partners Sponsor, LLC | 655.6K | 1.22% | 655.6K | — | 655.6K | 11.00 | OO | — | 2021-05-26 | ↗ |
| 9 | LLC | 590.4K | 1.24% | 590.4K | — | 590.4K | — | OO | Delaware | 2021-06-04 | ↗ |
| 10 | Ari Glass | 539.5K | 6.66% | — | 539.5K | — | 539.5K | HC | United States | 2018-02-12 | ↗ |
| 11 | Boothbay Absolute Return Strategies LP | 539.5K | 6.66% | — | 539.5K | — | 539.5K | PN | Delaware | 2018-02-12 | ↗ |
| 12 | HGC Investment Management Inc. | 480.7K | 5.32% | 480.7K | — | 480.7K | — | FI | Canada | 2019-02-13 | ↗ |
| 13 | ALEC N. LITOWITZ | 465.0K | 7.66% | — | 465.0K | — | — | HC, IN | United States of America | 2020-02-13 | ↗ |
| 14 | MAGNETAR CAPITAL PARTNERS LP | 465.0K | 7.66% | — | 465.0K | — | — | HC, PN | Delaware | 2020-02-13 | ↗ |
| 15 | MAGNETAR FINANCIAL LLC | 465.0K | 7.66% | — | 465.0K | — | — | IA, OO | Delaware | 2020-02-13 | ↗ |
| 16 | SUPERNOVA MANAGEMENT LLC | 465.0K | 7.66% | — | 465.0K | — | — | HC, OO | Delaware | 2020-02-13 | ↗ |
| 17 | S | 439.5K | 5.50% | — | 439.5K | — | 439.5K | PN | Delaware | 2017-12-08 | ↗ |
| 18 | Absolute Return Strategies LP | 300.0K | 3.32% | — | 300.0K | — | 300.0K | PN | Delaware | 2019-02-14 | ↗ |
| 19 | Fund Management, LLC | 300.0K | 3.32% | — | 300.0K | — | 300.0K | OO | Delaware | 2019-02-14 | ↗ |
| 20 | Glass | 300.0K | 3.32% | — | 300.0K | — | 300.0K | HC | States | 2019-02-14 | ↗ |
| 21 | Boothbay Fund Management, LLC | 48.4K | 0.61% | — | 48.4K | — | 48.4K | OO | Delaware | 2018-02-12 | ↗ |
| 22 | K2 & ASSOCIATES INVESTMENT MANAGEMENT INC. | — | 0.00% | — | — | — | — | CO | ONTARIO, CANADA | 2021-02-16 | ↗ |
| 23 | K2 Genpar 2017 Inc. | — | 0.00% | — | — | — | — | CO | Ontario, CANADA | 2021-02-16 | ↗ |
| 24 | L.P. | — | 0.00% | — | — | — | — | PN | Ontario, CANADA | 2021-02-16 | ↗ |
| 25 | OxFORD ASSET MANAGEMENT LLP | — | 0.00% | — | — | — | — | IA | UNITED KINGDOM | 2021-02-16 | ↗ |
| 26 | Polar Asset Management Partners Inc. | — | 0.00% | — | — | — | — | IA | Canada | 2020-04-10 | ↗ |
| 27 | SHAWN KIMEL INVESTMENTS, INC. | — | 0.00% | — | — | — | — | CO | ONTARIO, CANADA | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
37
+6 vs prev Q
New positions
10
Closed positions
7
Increased
22
Reduced
3
Put/Call ratio
1.01
Calls held
131.5K
Puts held
132.4K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 15.0K +15.0K (+100.0%) | 40.65M +40.7M (+100.0%) | 0.07% +0.068 pp | 0.04% +0.038 pp | USD2.71 +0.0% | 1 qtrs NEW |
| 2 | ANSON FUNDS MANAGEMENT LP | 3.04M +1.0M (+50.3%) | 8.25M +1.6M (+23.4%) | 13.69% +2.400 pp | 0.78% +0.172 pp | USD2.60 +4.2% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 729.8K +194.9K (+36.4%) | 1.98M +212.5K (+12.0%) | 3.28% +0.300 pp | 0.00% +0.000 pp | USD2.65 +2.3% | 7 qtrs — |
| 4 | COMMONWEALTH EQUITY SERVICES, LLC | 366.6K +366.6K (+100.0%) | 993.6K +993.6K (+100.0%) | 1.65% +1.649 pp | 0.00% +0.001 pp | USD2.71 +0.0% | 1 qtrs NEW |
| 5 | ADVISORSHARES INVESTMENTS LLC | 328.0K -14.1K (-4.1%) | 888.9K -240.2K (-21.3%) | 1.48% -0.432 pp | 0.15% -0.036 pp | USD2.53 +7.1% | 7 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 218.9K +33.0K (+17.8%) | 593.2K -20.2K (-3.3%) | 0.98% -0.052 pp | 0.00% +0.000 pp | USD2.57 +5.4% | 7 qtrs — |
| 7 | BLEAKLEY FINANCIAL GROUP, LLC | 117.2K +117.2K (+100.0%) | 317.6K +317.6K (+100.0%) | 0.53% +0.527 pp | 0.01% +0.006 pp | USD2.71 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 87.0K +10.7K (+14.0%) | 235.7K -16.0K (-6.4%) | 0.39% -0.034 pp | 0.00% +0.000 pp | USD2.70 +0.4% | 7 qtrs — |
| 9 | BLACKROCK, INC. | 82.7K +17.2K (+26.4%) | 224.0K +8.1K (+3.8%) | 0.37% +0.007 pp | 0.00% +0.000 pp | USD2.59 +4.6% | 6 qtrs — |
| 10 | GLOBAL RETIREMENT PARTNERS, LLC | 39.3K +39.3K (+100.0%) | 106.5K +106.5K (+100.0%) | 0.18% +0.177 pp | 0.00% +0.002 pp | USD2.71 +0.0% | 1 qtrs NEW |
| 11 | ONE WEALTH MANAGEMENT INVESTMENT & ADVISORY SERVICES, LLC | 37.9K +9.9K (+35.3%) | 102.6K +10.3K (+11.1%) | 0.17% +0.014 pp | 0.11% +0.005 pp | USD2.86 -5.2% | 7 qtrs — |
| 12 | CITADEL ADVISORS LLC | 35.8K +2.9K (+8.8%) | 97.0K -11.6K (-10.6%) | 0.16% -0.022 pp | 0.00% +0.000 pp | USD3.25 -16.6% | 2 qtrs — |
| 13 | JANE STREET GROUP, LLC | 30.6K +18.5K (+152.9%) | 82.9K +43.0K (+107.7%) | 0.14% +0.070 pp | 0.00% +0.000 pp | USD2.94 -7.8% | 2 qtrs — |
| 14 | NORTHERN TRUST CORP | 28.9K +346.0 (+1.2%) | 78.4K -15.9K (-16.9%) | 0.13% -0.029 pp | 0.00% +0.000 pp | USD2.06 +31.6% | 4 qtrs — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 27.8K -13.8K (-33.2%) | 75.3K -61.9K (-45.1%) | 0.13% -0.107 pp | 0.00% +0.000 pp | USD3.30 -17.9% | 7 qtrs — |
| 16 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 33.4K -8.6K (-20.4%) | 72.5K -53.5K (-42.4%) | 0.15% -0.084 pp | 0.00% -0.002 pp | USD3.30 -17.9% | 2 qtrs — |
| 17 | TWO SIGMA INVESTMENTS, LP | 17.4K -34.9K (-66.7%) | 47.3K -125.4K (-72.6%) | 0.08% -0.213 pp | 0.00% 0.000 pp | USD2.58 +5.0% | 4 qtrs — |
| 18 | POINT72 ASSET MANAGEMENT, L.P. | 16.0K +16.0K (+100.0%) | 43.3K +43.3K (+100.0%) | 0.07% +0.072 pp | 0.00% +0.000 pp | USD2.71 +0.0% | 1 qtrs NEW |
| 19 | ETHOS FINANCIAL GROUP, LLC | 11.9K +— (+0.0%) | 32.2K -7.0K (-17.9%) | 0.05% -0.013 pp | 0.00% -0.001 pp | USD3.30 -17.9% | 2 qtrs — |
| 20 | MORGAN STANLEY | 10.0K -1.1K (-9.5%) | 27.2K -9.4K (-25.7%) | 0.05% -0.017 pp | 0.00% +0.000 pp | USD2.88 -5.9% | 7 qtrs — |
| 21 | UBS GROUP AG | 3.5K -149.3K (-97.7%) | 9.6K -494.8K (-98.1%) | 0.02% -0.836 pp | 0.00% 0.000 pp | USD3.27 -17.1% | 7 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 3.2K -161.0 (-4.7%) | 8.8K -2.4K (-21.8%) | 0.01% -0.004 pp | 0.00% +0.000 pp | USD2.61 +3.8% | 7 qtrs — |
| 23 | SBI SECURITIES CO., LTD. | 2.5K +— (+0.0%) | 6.8K -1.5K (-17.9%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD2.55 +6.3% | 4 qtrs — |
| 24 | WELLS FARGO & COMPANY/MN | 2.0K +— (+0.0%) | 5.4K -1.2K (-17.9%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD2.19 +23.7% | 7 qtrs — |
| 25 | ROYAL BANK OF CANADA | 2.0K +2.0K (+100.0%) | 5.0K +5.0K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD2.71 +0.0% | 1 qtrs NEW |
| 26 | ADVISOR GROUP HOLDINGS, INC. | 90.00 -1.0K (-91.7%) | 243.00 -2.3K (-90.4%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD3.20 -15.3% | 5 qtrs — |
| 27 | JPMORGAN CHASE & CO | 34.00 +— (+0.0%) | 92.00 -20.0 (-17.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.24 +21.0% | 7 qtrs — |
| 28 | LARSON FINANCIAL GROUP LLC | 22.00 +— (+0.0%) | 60.00 -13.0 (-17.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.55 +6.3% | 7 qtrs — |
| 29 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.00 -323.0 (-99.7%) | 3.00 -1.1K (-99.7%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD3.00 -9.7% | 3 qtrs — |
| 30 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 1.00 +1.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +35.5% | 1 qtrs NEW |
| 31 | MARSHALL WACE, LLP | — -189.1K (-100.0%) | — -624.2K (-100.0%) | 0.00% -1.055 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
| 32 | RENAISSANCE TECHNOLOGIES LLC | — -128.2K (-100.0%) | — -423.0K (-100.0%) | 0.00% -0.715 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 33 | CAROLINA WEALTH ADVISORS, LLC | — -50.0 (-100.0%) | — -165.0 (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF PSIL | 6.22% | 2.76M | 1.84% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 439.8K | 0.60% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 1.26M | 0.05% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 1.8K | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 9.0K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 24.8K | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 4.24M | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 9.3K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 5.1K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 2.0K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
40.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+40,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-27 | Casper Joseph Michael | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.39 | 239.0K | 100,000 | D | ↗ |
| 2025-08-18 | B Group, Inc. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 3,000,000 | I | ↗ |
| 2025-04-09 | McBride Dennis | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.73 | 43.2K | 25,000 | D | ↗ |
| 2025-04-09 | Javitt Jonathan C | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 125,000 | 1.73 | 216.2K | 125,000 | D | ↗ |
| 2025-04-09 | Hurvitz Chaim | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 1.73 | 43.2K | 25,000 | D | ↗ |
| 2025-04-09 | Flynn Patrick John | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 1.73 | 86.5K | 50,000 | D | ↗ |
| 2025-02-07 | ABRAMS MICHAEL S | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 2.94 | 147.0K | 50,000 | D | ↗ |
| 2024-12-17 | Javitt Jonathan C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 40,000 | 1.17 | 46.8K | 84,634 | D | ↗ |
| 2024-11-18 | ABRAMS MICHAEL S | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-13 | VAN VOORHEES SETH | Officer | — | D | Employee Stock Option Plan (right to Buy) | 162,500 | 0.51 | 83.5K | 0 | — | ↗ |
| 2024-06-13 | McBride Dennis | Director | — | D | Stock Options (Right to buy) | 6,320 | 15.30 | 96.7K | 0 | — | ↗ |
| 2024-03-15 | Strassberg Ira S | Officer | — | D | Employee Stock Option Plan (Right to Buy) | 212,500 | 3.10 | 658.8K | 0 | — | ↗ |
| 2023-12-28 | Rehnquist Janet | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-13 | Narido Richard Clavano | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-30 | Hurvitz Chaim | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 70,000 | 0.29 | 20.1K | 570,000 | — | ↗ |
| 2023-08-30 | Gorovitz Aaron | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 35,000 | 0.32 | 11.2K | 105,000 | — | ↗ |
| 2023-08-23 | Javitt Jonathan C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.33 | 33.0K | 446,332 | — | ↗ |
| 2023-08-22 | Javitt Jonathan C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 200,000 | 0.32 | 64.4K | 346,332 | — | ↗ |
| 2022-12-31 | Javitt Jonathan C | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-16 | Willard Stephen H | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 per share | 50,000 | 1.17 | 58.5K | 50,000 | — | ↗ |
| 2022-12-16 | VAN VOORHEES SETH | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 per share | 30,000 | 1.10 | 33.0K | 46,337 | — | ↗ |
| 2022-12-07 | Javitt Jonathan C | Director | S-Sale | D | Common Stock, par value $0.001 per share | 400,000 | 1.00 | 400.0K | 12,899,997 | — | ↗ |
| 2022-11-30 | Javitt Daniel C. | Director | S-Sale | D | common stock | 8,441 | 1.50 | 12.7K | 9,634,793 | — | ↗ |
| 2022-11-29 | Javitt Daniel C. | Director | S-Sale | D | common stock | 13,730 | 1.50 | 20.7K | 9,643,234 | — | ↗ |
| 2022-11-28 | Flynn Patrick John | Director | P-Purchase | A | Common Stock, par value $0.001 per share | 2,500 | 1.24 | 3.1K | 40,209 | — | ↗ |
| 2022-11-25 | VAN VOORHEES SETH | Officer | P-Purchase | A | Common Stock, par value $0.001 per share | 7,021 | 1.11 | 7.8K | 16,337 | D | ↗ |
| 2022-11-18 | Hurvitz Chaim | Director | P-Purchase | A | Common Stock | 40,408 | 1.10 | 44.4K | 500,000 | D | ↗ |
| 2022-11-17 | Javitt Daniel C. | Director | S-Sale | D | common stock | 33,018 | 1.05 | 34.7K | 9,656,964 | — | ↗ |
| 2022-11-17 | Hurvitz Chaim | Director | P-Purchase | A | Common Stock | 171,780 | 1.08 | 185.5K | 459,592 | D | ↗ |
| 2022-11-16 | Javitt Daniel C. | Director | S-Sale | D | common stock | 133,719 | 1.02 | 136.4K | 9,689,982 | — | ↗ |
| 2022-11-16 | Hurvitz Chaim | Director | P-Purchase | A | Common Stock | 287,812 | 0.99 | 284.9K | 287,812 | D | ↗ |
| 2022-11-11 | Javitt Daniel C. | Director | S-Sale | D | common stock | 49,200 | 1.01 | 49.5K | 9,823,701 | — | ↗ |
| 2022-10-21 | Hurvitz Chaim | Director | A-Award | A | Employee Stock Option | 162,660 | 0.75 | 122.0K | 381,083 | D | ↗ |
| 2022-10-21 | Gorovitz Aaron | Director | A-Award | A | Employee Stock Option | 162,660 | 0.00 | — | 162,660 | — | ↗ |
| 2022-10-21 | Glied Sharon | Director | A-Award | A | Employee Stock Option | 162,660 | 0.00 | — | 228,097 | — | ↗ |
| 2022-10-21 | Flynn Patrick John | Director | A-Award | A | Employee Stock Option | 162,660 | 0.00 | — | 162,660 | — | ↗ |
| 2022-07-29 | Javitt Daniel C. | Director | S-Sale | D | Common Stock | 784,063 | 1.01 | 791.4K | 9,872,901 | — | ↗ |
| 2022-07-12 | Willard Stephen H | Director / Officer | — | D | Restricted Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2022-07-01 | Javitt Daniel C. | Director | G-Gift | D | Common Stock | 2,000,000 | 0.00 | — | 10,656,964 | — | ↗ |
| 2022-06-03 | Javitt Daniel C. | Director | S-Sale | D | Common Stock | 115,657 | 0.67 | 76.9K | 12,743,423 | — | ↗ |
| 2022-06-01 | Javitt Jonathan C | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.58 | 58.0K | 146,332 | — | ↗ |
| 2022-05-26 | McMaster Herbert Raymond | Director | — | D | Employee Stock Option (Right to buy) | 3,845 | 23.41 | 90.0K | 0 | — | ↗ |
| 2022-03-08 | Besthof Robert | Officer | A-Award | A | Employee Stock Option | 100,000 | 2.61 | 261.0K | 347,200 | — | ↗ |
| 2021-09-15 | Besthof Robert | Officer | S-Sale | D | Common Stock | 40,000 | 11.76 | 470.4K | 23,710 | — | ↗ |
| 2021-09-02 | Daigneault Alessandra | Officer | C-Conversion | D | Employee Stock Option (Right to buy) | 28,916 | 3.07 | 88.8K | 71,924 | — | ↗ |
| 2021-08-26 | McMaster Herbert Raymond | Director | M-Exempt | A | Common Stock | 18,300 | 2.22 | 40.6K | 18,300 | — | ↗ |
| 2021-08-23 | Daigneault Alessandra | Officer | S-Sale | D | Common Stock | 33,715 | 13.11 | 442.0K | 0 | — | ↗ |
| 2021-08-19 | Daigneault Alessandra | Officer | C-Conversion | D | Employee Stock Option (Right to buy) | 43,000 | 3.07 | 132.0K | 100,840 | — | ↗ |
| 2021-08-16 | Besthof Robert | Officer | C-Conversion | D | Employee Stock Option (Right to buy) | 100,000 | 0.20 | 20.0K | 247,200 | — | ↗ |
| 2021-07-16 | Javitt Daniel C. | 10% Owner | G-Gift | D | Common Stock | 434,594 | 0.00 | — | 13,537,270 | — | ↗ |
| 2021-05-26 | McMaster Herbert Raymond | Director | — | D | Employee Stock Option (Right to buy) | 45,086 | 2.22 | 100.1K | 0 | — | ↗ |
| 2021-05-24 | Troy Daniel | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Javitt Jonathan C | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Javitt Daniel C. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Hurvitz Chaim | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Gorovitz Aaron | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Glied Sharon | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Fricker William | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Flynn Patrick John | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-24 | Daigneault Alessandra | Officer | A-Award | A | Common Stock | 6,320 | 0.00 | — | 6,320 | — | ↗ |
| 2021-05-24 | Big Rock Partners Sponsor, LLC | 10% Owner | C-Conversion | A | Common Stock | 27,250 | 0.00 | — | 519,315 | — | ↗ |
| 2021-05-24 | Besthof Robert | Officer | A-Award | A | Employee Stock Option (Right to buy) | 347,200 | 0.21 | 72.9K | 347,200 | — | ↗ |
| 2021-05-24 | BRAC Lending Group LLC | 10% Owner | D-Return | D | Common Stock | 869,565 | 0.00 | — | 590,435 | — | ↗ |
| 2020-03-13 | Polar Asset Management Partners Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 29,464 | 10.60 | 312.3K | 488,036 | — | ↗ |
| 2020-02-27 | Polar Asset Management Partners Inc. | 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 517,500 | — | ↗ |
| 2018-11-20 | ACKERMAN RICHARD | Director / Officer | S-Sale | D | Common Stock | 1,500,000 | 1.00 | 1.50M | 225,000 | — | ↗ |
| 2018-11-17 | BRAC Lending Group LLC | 10% Owner | — | I | Unit Purchase Option (Right to Buy) | 80,000 | 10.00 | 800.0K | 0 | — | ↗ |
| 2017-11-29 | ACKERMAN RICHARD | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 22,500 | 10.00 | 225.0K | 272,500 | — | ↗ |
| 2017-11-20 | Wittman Lori | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | Taylor Troy T | Director | — | I | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | REX ALBERT G. | Director | — | I | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | Koenig Stuart F. | Director | — | D | No securities are beneficially owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | KIM BENNETT | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | FONG MICHAEL | Director | — | I | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | BIRDOFF RICHARD | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-20 | ACKERMAN RICHARD | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 250,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-80.9K
Shares Outstanding
17.29M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Jonathan Javitt Chief Executive Officer, Chief Scientist and Chairman | 575.0K | 250.0K | — | — | — | — | 825.0K | 0.00% | ↗ |
| 2 | 2024 | Richard Narido Former Chief Financial Officer | 435.0K | — | — | — | — | — | 435.0K | 0.00% | ↗ |
| 3 | 2024 | Stephen Willard Former Chief Executive Officer | 395.8K | — | — | — | — | — | 395.8K | 0.00% | ↗ |
| 4 | 2024 | Matthew Duffy Chief Business Officer | 338.0K | — | — | — | — | — | 338.0K | 0.00% | ↗ |
| 5 | 2024 | Michael Abrams Chief Financial Officer | 20.3K | — | — | — | — | — | 20.3K | 0.00% | ↗ |
| 6 | 2023 | Jonathan Javitt Chairman and Chief Scientist | 602.8K | — | — | — | — | 27.4K | 630.2K | 0.00% | ↗ |
| 7 | 2023 | Jonathan Javitt Chief Executive Officer, Chief Scientist and Chairman | 602.8K | — | — | — | — | 27.4K | 630.2K | 0.00% | ↗ |
| 8 | 2023 | Stephen Willard Chief Executive Officer | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 9 | 2023 | Stephen Willard Former Chief Executive Officer | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 10 | 2023 | Richard Narido Former Chief Financial Officer | 255.0K | — | — | 43.0K | — | — | 298.0K | 14.43% | ↗ |
| 11 | 2023 | Richard Narido Chief Financial Officer | 255.0K | — | — | 43.0K | — | — | 298.0K | 14.43% | ↗ |
| 12 | 2023 | Matthew Duffy Chief Business Officer | 60.0K | — | — | 99.0K | — | — | 159.0K | 62.26% | ↗ |
| 13 | 2022 | Ira Strassberg Former Chief Financial Officer and Treasurer | 307.9K | — | — | 13.00 | — | — | 1.31M | 0.00% | ↗ |
| 14 | 2022 | Jonathan Javitt Chairman and Chief Scientist | 867.4K | — | — | — | — | 6.3K | 873.7K | 0.00% | ↗ |
| 15 | 2022 | Jonathan Javitt, M.D., M.P.H. Chief Scientist and former Chief Executive Officer | 7.00 | — | — | — | — | 6.3K | 873.7K | 0.00% | ↗ |
| 16 | 2022 | Stephen H. Willard Chief Executive Officer | 233.9K | — | 566.0K | — | — | — | 799.9K | 70.76% | ↗ |
| 17 | 2022 | Stephen Willard Chief Executive Officer | 233.9K | — | 566.0K | — | — | — | 799.9K | 70.76% | ↗ |
| 18 | 2022 | Robert Besthof Former Chief Commercial and former Interim Chief Executive Officer | 9.00 | — | — | 195.0K | — | — | 651.2K | 29.94% | ↗ |
| 19 | 2022 | Alessandra Daigneault Former Chief Corporate Officer, General Counsel and Secretary | 162.8K | 160.0K | — | — | — | 262.0K | 584.8K | 0.00% | ↗ |
| 20 | 2022 | Seth Van Voorhees Former Chief Financial Officer and Treasurer | 220.0K | — | — | 134.9K | — | — | 354.9K | 38.01% | ↗ |
| 21 | 2022 | Riccardo Panicucci CMC and Technical Operations Advisor | 9.00 | — | — | — | — | — | 240.0K | 0.00% | ↗ |
| 22 | 2021 | Randy Guggenheimer Chief Business Officer | 143.8K | — | — | 3.44M | — | — | 3.59M | 95.99% | ↗ |
| 23 | 2021 | Alessandra Daigneault Chief Corporate Officer, General Counsel and Secretary | 228.0K | 290.0K | — | 1.75M | — | 3.0K | 2.28M | 77.11% | ↗ |
| 24 | 2021 | Alessandra Daigneault Former Chief Corporate Officer, General Counsel and Secretary | 228.0K | 100.0K | — | 1.75M | — | 3.0K | 2.09M | 84.13% | ↗ |
| 25 | 2021 | Jonathan Javitt, M.D., M.P.H. Chief Scientist and former Chief Executive Officer | 275.0K | — | — | — | — | 102.3K | 377.3K | 0.00% | ↗ |
| 26 | 2021 | Jonathan Javitt Director and Former Chief Executive Officer | 275.0K | — | — | — | — | 102.3K | 377.3K | 0.00% | ↗ |
| 27 | 2021 | Robert Besthof Chief Commercial and Patient Officer and Head of Operations and Interim Chief Executive Officer | 264.0K | — | — | — | — | — | 264.0K | 0.00% | ↗ |
| 28 | 2021 | Robert Besthof Former Chief Commercial and former Interim Chief Executive Officer | 9.00 | — | — | — | — | — | 264.0K | 0.00% | ↗ |
| 29 | 2020 | Robert Besthof Chief Commercial and Patient Officer and Head of Operations and Interim Chief Executive Officer | 252.0K | — | — | 744.1K | — | — | 996.1K | 74.70% | ↗ |
| 30 | 2020 | Jonathan Javitt Director and Former Chief Executive Officer | 275.0K | 325.0K | — | — | — | 14.6K | 614.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan C. Javitt | Co-Founder, Chairman, CEO & Chief Scientist Officer | 846.8K | — |
| Michael S. Abrams | CFO & Treasurer | 363.1K | male |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | 240.0K | male |
| Dennis K. McBride | Chief Strategy Officer & Director | 38.5K | — |
| Philip T. Lavin | Chief Methodologist | — | — |
| Suzanne Messere | Investor Relations | — | — |
| Glenn Tyson | Chief Commercial Officer | — | male |
| Joseph Casper | Chief Operating Officer | — | male |
| Joshua C. Brown | Chief Medical Innovation Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NRXP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
